Sijme Zeilemaker

Sijme Zeilemaker has over 13 years of experience in various corporate roles in biotech companies ranging from preclinical to phase II development. Prior to Sapreme, Sijme was CEO at Immunetune, a preclinical stage biotech with DNA-based vaccines, and COO at Mendus (previously Immunicum), a clinical stage biotech with cell-based immunotherapies listed at the Nasdaq Stockholm. He joined Immunicum as part of a small team and supported the growth of the company through a collaboration with Pfizer and Merck KGaA, three financing rounds, and the merger with DCprime. Before Immunicum, Sijme held various business development roles at InteRNA Technologies in the field of microRNA therapeutics and to-BBB technologies in the field of lipid nanoparticles, transitioning these companies from preclinical to clinical stage. Sijme has a MSc in Biomedical Sciences from Leiden University, the Netherlands.